About the ORBEX Study

The Oral Bacterial Extract (ORBEX) Study is a three year study to identify if a daily capsule of Broncho-Vaxom will help prevent or delay young children from developing wheezing or asthma-like symptoms. Broncho-Vaxom has already been used by 43 million children in countries all over the world.

Participants in the trial will be randomly selected to either take the investigated product or a placebo (non-active ingredients) for 10 consecutive days each month for two years, and then observed for one year. The product, Broncho-Vaxom ® , is a combination of inactive bacterial extracts, simply added as a powder to a small amount of liquid. The placebo is given in the same manner.

Modern life has decreased exposure to these naturally occurring microbes, which have resulted in immune systems that are more susceptible to the development of asthma. The ORBEX Study proposes that giving Broncho-Vaxom to children in the early years of life may prevent wheezing and the wheezing illnesses that lead to persistent asthma.